As shown in Fig. 5b, XLF expression was significantly increased in patients with HCC who underwent TACE compared to those who did not, indicating that the delivery of drugs by TACE may directly or indirectly stimulate XLF expression. The gene discussed is NHEJ1; the disease is hepatocellular carcinoma.